These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 32915057)
1. Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia. Ceccato A; Mendez R; Ewig S; de la Torre MC; Cilloniz C; Gabarrus A; Prina E; Ranzani OT; Ferrer M; Almirall J; Menendez R; Torres A Ann Am Thorac Soc; 2021 Feb; 18(2):257-265. PubMed ID: 32915057 [No Abstract] [Full Text] [Related]
2. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Prina E; Ranzani OT; Polverino E; Cillóniz C; Ferrer M; Fernandez L; Puig de la Bellacasa J; Menéndez R; Mensa J; Torres A Ann Am Thorac Soc; 2015 Feb; 12(2):153-60. PubMed ID: 25521229 [TBL] [Abstract][Full Text] [Related]
3. Risk factors for drug-resistant pathogens in immunocompetent patients with pneumonia: Evaluation of PES pathogens. Ishida T; Ito A; Washio Y; Yamazaki A; Noyama M; Tokioka F; Arita M J Infect Chemother; 2017 Jan; 23(1):23-28. PubMed ID: 27729192 [TBL] [Abstract][Full Text] [Related]
4. Risk factors for community-onset pneumonia caused by drug-resistant pathogens: A prospective cohort study. Barreto JV; Dias CC; Cardoso T Eur J Intern Med; 2022 Feb; 96():66-73. PubMed ID: 34670681 [TBL] [Abstract][Full Text] [Related]
5. Validation of a Community-Acquired Pneumonia Score To Improve Empiric Antibiotic Selection at an Academic Medical Center. Oliver MB; Fong K; Certain L; Spivak ES; Timbrook TT Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33257449 [TBL] [Abstract][Full Text] [Related]
6. Challenges in severe community-acquired pneumonia: a point-of-view review. Torres A; Chalmers JD; Dela Cruz CS; Dominedò C; Kollef M; Martin-Loeches I; Niederman M; Wunderink RG Intensive Care Med; 2019 Feb; 45(2):159-171. PubMed ID: 30706119 [TBL] [Abstract][Full Text] [Related]
7. Community-acquired pneumonia with risk for drug-resistant pathogens. Fleming V; Buck B; Nix N; Kumar P; Southwood R South Med J; 2013 Mar; 106(3):209-16. PubMed ID: 23462490 [TBL] [Abstract][Full Text] [Related]
8. Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis. Torres A; Cillóniz C; Ferrer M; Gabarrús A; Polverino E; Villegas S; Marco F; Mensa J; Menéndez R; Niederman M Eur Respir J; 2015 May; 45(5):1353-63. PubMed ID: 25614173 [TBL] [Abstract][Full Text] [Related]
9. Predicting risk of drug-resistant organisms in pneumonia: moving beyond the HCAP model. Webb BJ; Dascomb K; Stenehjem E; Dean N Respir Med; 2015 Jan; 109(1):1-10. PubMed ID: 25468412 [TBL] [Abstract][Full Text] [Related]
10. Predicting antibiotic resistance to community-acquired pneumonia antibiotics in culture-positive patients with healthcare-associated pneumonia. Madaras-Kelly KJ; Remington RE; Fan VS; Sloan KL J Hosp Med; 2012 Mar; 7(3):195-202. PubMed ID: 22038859 [TBL] [Abstract][Full Text] [Related]
11. [Predictors of drug-resistant pathogens in community-onset pneumonia: Are factors considered in health-care-associated pneumonia useful in the emergency department?]. Torres Bonafonte OH; Gil Olivas E; Pérez Macho E; Pacho Pacho C; Mateo Roca M; Casademont Pou J; Ruiz Hidalgo D Emergencias; 2017 Oct; 29(5):306-312. PubMed ID: 29077289 [TBL] [Abstract][Full Text] [Related]
12. Ceftobiprole medocaril for the treatment of community-acquired pneumonia. Falcó V; Burgos J; Almirante B Expert Opin Pharmacother; 2018 Sep; 19(13):1503-1509. PubMed ID: 30198789 [TBL] [Abstract][Full Text] [Related]
13. Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use. Rhee C; Kadri SS; Dekker JP; Danner RL; Chen HC; Fram D; Zhang F; Wang R; Klompas M; JAMA Netw Open; 2020 Apr; 3(4):e202899. PubMed ID: 32297949 [TBL] [Abstract][Full Text] [Related]
14. PES Pathogens in Severe Community-Acquired Pneumonia. Cillóniz C; Dominedò C; Nicolini A; Torres A Microorganisms; 2019 Feb; 7(2):. PubMed ID: 30759805 [TBL] [Abstract][Full Text] [Related]
15. Comparison of community-acquired pneumonia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus producing the Panton-Valentine leukocidin. Vardakas KZ; Matthaiou DK; Falagas ME Int J Tuberc Lung Dis; 2009 Dec; 13(12):1476-85. PubMed ID: 19919764 [TBL] [Abstract][Full Text] [Related]
16. Choosing antibiotic therapy for severe community-acquired pneumonia. Martin-Loeches I; Garduno A; Povoa P; Nseir S Curr Opin Infect Dis; 2022 Apr; 35(2):133-139. PubMed ID: 35190510 [TBL] [Abstract][Full Text] [Related]
17. Antimicrobial drug-resistant microbes associated with hospitalized community-acquired and healthcare-associated pneumonia: a multi-center study in Taiwan. Wu CL; Ku SC; Yang KY; Fang WF; Tu CY; Chen CW; Hsu KH; Fan WC; Lin MC; Chen W; Ou CY; Yu CJ J Formos Med Assoc; 2013 Jan; 112(1):31-40. PubMed ID: 23332427 [TBL] [Abstract][Full Text] [Related]
18. Antibiotic Use and Outcomes After Implementation of the Drug Resistance in Pneumonia Score in ED Patients With Community-Onset Pneumonia. Webb BJ; Sorensen J; Mecham I; Buckel W; Ooi L; Jephson A; Dean NC Chest; 2019 Nov; 156(5):843-851. PubMed ID: 31077649 [TBL] [Abstract][Full Text] [Related]
19. [Analysis on distribution and drug resistance of pathogen caused community-onset bloodstream infection]. Mao S; Ge Z; Zhao H; Cao J; Xia Z Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Jan; 31(1):67-72. PubMed ID: 30707872 [TBL] [Abstract][Full Text] [Related]